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SUMMARY
A cross-sectional study with internal comparison groups was conducted to describe sociodemographic characteristics, as well
as verify the association between the type of antiretroviral treatment used and hyperglycemia and hyperlipidemia, with special
attention to the use of HIV protease inhibitors. The data was obtained through an interview questionnaire, as well as blood and
urine samples that were collected for the laboratory exams. A total of 418 patients were interviewed. 46 of these, however, met the
exclusion criteria. The sample was therefore composed by 372 HIV positive patients, attended at the laboratory of the Correia
Picanço State Hospital for the collection of blood, to estimate the HIV viral load and/or TCD4 cell counts from August to
November 2000. The association between the variables was tested using the chi-square test and the p-value. A multiple logistic
regression analysis was carried out to adjust for potential confounding factors. A greater frequency of patients with high glucose
levels was observed among those making use of antiretroviral therapy without protease inhibitors, but the number of patients
limited the comparisons. An association was verified between the total serum cholesterol level and the use of HIV protease
inhibitors (p = 0.047) even after controlling for age. An association was also observed between the triglyceride levels and the use
of HIV protease inhibitors, which remained after adjustment for age, sex and creatinine levels (p < 0.001). The levels of glucose
and TSH, the presence of proteinuria and the practice of physical activity were not associated either with the levels of cholesterol
or with the levels of tryglicerides thus they were not confounders of the associations described.
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INTRODUCTION
The employment of therapeutic regimens with the combination of
antiretroviral drugs has shown an impact on the survival rate of patients
with acquired immune deficiency syndrome in recent years. Despite
the advances obtained, starting with the earliest use of PIs in 1995
there began to emerge the first reports of alterations in the lipid
metabolism related to this group of drugs. Insulin resistance, increase
in plasmatic lipids, and fat redistribution have been indicated as
metabolic complications related to the use of ARV9 regimens. The
pathogenesis of this triad of metabolic alterations is as yet unknown.
There is evidence that HIV-1 protease inhibitors have high affinity for
the catalytic site of HIV-1 protease and that the latter has molecular
homologies with two human proteins involved in lipid metabolism:
cytoplasmic retinoid-acid binding protein type 1 (CRABP-1) and low
density lipoprotein-receptor-related protein (LRP). It was then
hypothesized that the binding and inhibition of CRABP-1 by the HIV-
1 protease inhibitors would lead to an increased apoptosis of peripheral
adipocytes, with reduced fat storage and lipid release; besides that, the
inhibition of LRP would exacerbate secondary hyperlipidemia, resulting
in central obesity, breast fat deposition and insulin resistance4.
It has also been suggested that the components of this metabolic
syndrome are not the expression of a single entity with a single cause
and that several factors may potentially influence its manifestation18.
A number of contributing factors have been referred, such as the
duration of the ARV treatment, the duration of the HAART regimen
employed, modifications in the viral load and regimen of a previous
treatment.
There are as yet few studies in the literature, on the association
between dyslipidemia and ARV treatment for HIV that have an
analytical approach, i.e., that have a (concurrent) comparison group
and perform mutual adjustment for potential confounders that may
distort the magnitude of the estimated association. Furthermore, in
the national literature, data on this problem are scarce, and it is not
clear whether there are characteristics of our population that may
influence this association.
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The objective of this study was to compare the glucose levels, total
cholesterol and triglycerides in three groups of patients - one group
infected with the HIV without ARV treatment; another receiving ARV
without PIs; and a third group of patients receiving ARV treatment
with PIs - controlling for potential confounding factors.
MATERIAL AND METHODS
Study design: Through a cross-sectional study with internal control
groups, we evaluated three hundred seventy-two patients (273 men
and 99 women) with HIV infection in attendance at the laboratory of
the Correia Picanço Hospital for a viral load count and/or CD4 cell
count during the period from August to November 2000. Patients were
excluded from the study if, at the time of the interview, they had eaten
or drunk anything in the previous 12 hours; they had ingested alcohol
within the previous 24 hours; they reported having diabetes mellitus
or dyslipidemia before beginning the ARV treatment for the HIV
infection.
The estimation of the sample size was based on the difference
between proportions and the following parameters were considered: α
= 5%, β = 20% and power = 80%. In relation to increased glycemia
level, we assumed a similar frequency of that of the general population
(non-diseased), that is, 7%1 for individuals with HIV/AIDS without
ARV treatment, and 21% among the patients in ARV treatment with
PIs, taking the use of ritonavir2 as the reference. Based on these
estimates, the sample size calculated was 109 individuals in each group.
Concerning dyslipidemia, we considered frequencies of 28% for
the group of patients who had never received a PI5, and 53% for patients
receiving ARV treatment with PIs19. With these parameters, the sample
size calculated was 67 individuals in each group.
We tested the association of the dependent variables (total
cholesterol and triglycerides) with the main exposure - the type of
antiretroviral regimen - as well as with the potential confounding
factors. In order to test the associations, we employed the qui-square
test, establishing a p value < 0.05 as statistically significant. The
adjustment for the potential confounding factors was carried out by
way of a multiple logistic regression.
Data entry double with a later comparison of the two files using
the VALIDATE resource. Data analysis was processed on the EPI-INFO
6.0 and Statistical Package for Social Sciences - PC.
Data collection: This study was approved by ethical committee at
the Correia Picanço Hospital. Patients were referred to the laboratory
of the Correia Picanço Hospital by their physicians to have their blood
collected for CD4 cell count and viral load. After having received a
clear explanation of the objectives of the study and having signed the
informed consent, patients answered a questionnaire, supplying
information regarding gender, age, marital status, place of origin, length
of time with HIV infection, whether or not they had made use of ARV
treatments in the previous six months, the ARV regimen used, and the
practice of physical activities. Medical records were used to confirm
the information given on ARV treatment. Height and weight were
assessed for calculating the Body Mass Index. Blood was drawn for
laboratory testing, requested either for routine evaluation or for the
investigation. The levels of glucose, total cholesterol and triglycerides,
as well as urea, creatinine and TSH were estimated; glucose levels
were measured after 12 hours of fasting. Urine samples were taken to
detect the presence of proteinuria, which could express the concomitant
presence of clinical conditions such as renal failure, hypothyroidism
and nephrotic syndrome. The cutoff points for the categorization of
the dependent variables (glucose, total cholesterol and triglycerides)
was based on the guidelines of the American Diabetes Association and
NCEP III.
Standardization of techniques: All measurements were obtained
under fasting conditions and just one physician performed the
biochemical laboratory exams, under standardized conditions. The
concentration values of glucose, total cholesterol, triglycerides and
urea was determined utilizing the enzymatic method DOLES®. The
concentration values of LDL cholesterol were determined through the
Friedwald equation. The concentration values of creatinine were
determined by the colorimetric method DOLES® through the Jaffe
reaction. To determine the presence of proteinuria, reagent tapes were
used for urine analysis Multistix®, Bayer. TSH levels were measured
in a randomly chosen sub-sample of patients (n = 98) and were carried
out through an automatized system by way of an immuno-enzymatic
assay of micro-particles MEIA-Imx and MEIA-Axsym.
RESULTS
General characteristics of the study population: Over a period
of four months 372 patients were studied whose characteristics are
described in Table 1. They were mainly males (73.4%), and aged 30 to
39 years. One hundred ninety-five individuals (52.4%) had a normal
Body Mass Index (BMI) and 81.7% referred to practice no physical
exercise.
In relation to the time elapsed since the serological diagnosis, one
third of the patients informed that they had known about their
serological status between two and five years before. Two hundred and
fifty nine (69.6%) patients had used some type of ARV medication for
the HIV infection in the previous six months; 36.6% of them were
treated with ARV containing PIs, 29.6% had received ARV treatment
without PIs and 30.4% had never undergone ARV treatment.
Concerning the creatinine levels 74.7% of the patients exhibited
creatinine levels within the normal range and, regarding the presence
of proteinuria, 86.8% were negative.
The glucose levels, total cholesterol, triglycerides and HDL
cholesterol were analyzed in relation to the ARV treatment, three groups
being considered: those who had never had an ARV treatment, those
who received a regimen without PIs and those who had a regimen
which included PIs (Table 2).
Three hundred and sixty two (97.2%) individuals had normal glucose
levels. Seven (out of ten) of those in the group with elevated glycemia
were patients in ARV treatment without PIs, but the low number of
patients with altered glucose levels precluded a statistical analysis. When
the total cholesterol was analyzed, it was observed that most of patients
(79.9%) had normal levels. Among those who exhibited elevated levels,
51.4% (37/72) were receiving ARV treatment with PIs. Regarding the
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Table 2
Distribution of HIV positive individuals according to type of ARV treatment
and glucose, total cholesterol, triglycerides and HDL cholesterol levels. August
to November 2000
Biochemistry
Glucose
Type of ARV Normal Elevated χ2 p value
treatment n % n %
Never had ARV 112 99.1 01 0.9
Without PIs 103 93.6 07 6.4
With PIs 134 98.5 02 1.5
Total 349 97.2 10 2.8 * **
Total Cholesterol
Normal Elevated
Never had ARV 97 85.8 16 14.2
Without PIs 91 82.7 19 17.3
With PIs 99 72.8 37 27.2
Total 287 79.9 72 20.1 7.318 0.026
HDL Cholesterol
Normal Low
Never had ARV 46 40.7 67 59.3
Without PIs 51 46.4 59 53.6
With PIs 57 41.9 79 58.1
Total 154 42.9 205 57.1 0.815 0.665
Triglycerides
Normal Borderline Elevated
Never had ARV 79 69.9 19 16.8 15 13.3
Without PIs 62 56.4 24 21.8 24 21.8
With PIs 48 35.6 31 23.0 56 41.5
Total 189 52.8 74 20.7 95 26.5 35.13 < 0.001
* χ2 not calculated; ** p value undetermined
Table 1
Distribution of HIV seropositive individuals according to biological
characteristics and ARV treatment
N %
Age group
12 - 29 90 24.5
30 - 39 171 45.7
40 - 49 86 23.4
> 50 25  6.4
Sex
Male 273 73.4
Female 99 26.6
BMI
Undernourished 58 15.6
Normal 195 52.4
Over weight 99 26.6
Obesity 19  5.1
Morbid obesity 01  0.3
Time since diagnosis (months)
≤ 6 64 17.2
6 - 12 40 10.8
13 - 24 61 16.4
25 - 60 127 34.1
> 60 80 21.5
Type of ARV treatment
Never had treatment 113 30.4
Without PIs 110 29.6
With PIs 136 36.6
Other associations 06  1.6
Not informed 07  1.8
LDL*
Normal 293 84.4
Borderline 38 11.0
High 16  4.6
Creatinine
Normal 278 74.7
High 94 25.3
Proteinuria
Negative 323 86.8
Positive (+1) 40 10.8
Positive (+2 and +3) 09  2.4
Total 372 100.0
* 25 individuals had triglycerides levels higher than 400 mg/dL
triglycerides, 52% of the individuals sampled presented normal levels,
20.2% presented borderline levels and 27.8% presented elevated levels.
Among the latter two groups, 41.9% (31/74) and 58.9% (56/95),
respectively, were receiving ARV treatment with PIs. Concerning the
levels of HDL cholesterol, 57.1% of the sample were composed of
individuals with levels below normal. There was a statistically significant
association between the levels of total cholesterol and triglycerides and
the use of the ARV treatment. This association was not found when the
HDL cholesterol was evaluated (Table 2).
Association between the values of glucose, total cholesterol and
triglycerides and the potential confounding factors (independent
variables):
Glycemia: At the univariate analysis we found no statistically
significant association between glucose levels and gender (Fisher: p =
1.00) and age group (χ2: p = 0.107).
Total cholesterol: Among the associations tested (sex, age-group,
physical exercise, glucose levels, creatinine and proteinuria) it was
found a statistically significant association between the levels of total
cholesterol and age group of the patient (χ2 = 4.235, p-value = 0.040).
Triglycerides: Statistically significant association was found
between the levels of triglycerides and gender (χ2 = 17.12, p-value <
0.001), age group (χ2 = 13.72, p-value = 0.001) and creatinine levels
(χ2 = 16.101, p-value < 0.001). The association with triglycerides was
not significant for the following variables: physical exercise, glucose
level and proteinuria.
Association between total cholesterol and triglycerides and the
76
ARAÚJO, P.S.R.; XIMENES R.A.A.; LOPES, C.F.C.; DUARTE, J.Y.; SILVA, M.M. & CARNEIRO, E.M. - Antiretroviral treatment for HIV infection/AIDS and the risk of developing
hyperglycemia and hyperlipidemia. Rev. Inst. Med. trop. S. Paulo, 49(2): 73-78, 2007.
type of antiretroviral treatment, adjusting for the potential
confounding factors through a multiple logistical regression:
Total cholesterol: Adjusting for the effect of each other, the type
of ARV treatment and age group by multiple logistical regression, it
was found that the two variables remained in the model, indicating an
independent association with each of them (Table 3) (The value of the
maximum likelihood ratio for the removal of each of the variables
was: Type of ARV treatment: maximum likelihood ratio = 6.093,
degree of freedom = 2, p value = 0.0475; Age group: maximum
likelihood ratio = 3.398; degree of freedom = 1; p value = 0.0653).
Triglycerides: To adjust the effect of each of the variables for
each other through multiple logistical regression, the dependent
variable, i.e., triglyceride levels, was transformed in a dychotomous
variable: normal triglyceride/abnormal triglyceride (borderline
triglyceride + elevated triglyceride). It was observed that all variables
remained in the final model, indicating that they are independently
associated with the triglyceride levels. (Table 4) (The value of the
maximum likelihood ratio for the removal of each of the variables
from the model was: Type of ARV treatment: maximum likelihood
ratio = 21.335, degree of freedom = 2; p value < 0.0001; Age group:
maximum likelihood ratio = 7.624, degree of freedom = 1, p value =
0.0058; Creatinine: maximum likelihood ratio = 3.632, degree of
freedom = 1, p value = 0.0567; Gender: maximum likelihood ratio =
9.074, degree of freedom = 1, p value = 0.0026).
DISCUSSION
As a combination of at least three types of drugs including
nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside
reverse transcriptase inhibitors (NNRTI) and protease inhibitors (PIs),
HAART is currently used to control the replication of HIV and AIDS.
Starting in 1995, with the first reports of the adverse effects of the
initial representatives of the PI class, ritonavir, saquinavir and indinavir,
several studies3,8,10,11,12,21,23 have driven attention to the fact that these
drugs have been associated with an abnormal fat redistribution
syndrome, which can raise the cholesterol and triglycerides levels, as
well as cause insulin resistance. The metabolic alterations resulting
from HAART may also be present in patients receiving regimens
containing NRTI without the use of PIs, especially with stavudine.
This suggests that PIs may not be the only ARV agents implicated in
these alterations. The finding of relative risk of 1.95 of developing
lipid redistribution in groups of patients receiving stavudine when
compared to zidovudine after 14 months of treatment corroborates with
this hypothesis19. A cohort study involving 277 participants14 evaluated
the relative contributions of NRTIs and PIs as determinants of fat loss
in patients infected with HIV. The study suggested that the NRTIs
have an independent contribution toward the metabolic syndrome, but
the PIs seem to be the main factors and probably act in synergy with
the NRTIs. The nucleoside analogues seem to predispose the individuals
to a slowly progressive fat loss that is markedly accelerated when a PI
is combined to the ARV regimen.
Our results showed an increased chance of hypercholesterolemia
and hypertriglyceridemia in patients receiving a PI-based antiretroviral
regimen. Some aspects of our study deserve further comments. First,
one of the characteristics that differentiates ours from most of other
previous studies is the fact that we analyzed the potential confounding
factors for hyperlipidemia, such as diabetes mellitus, primary
hyperthyroidism, renal failure and nephrotic syndrome, which are
recommended by the NCEP III, as well as gender, age group and the
practice of exercise. Adjustment for these variables was performed,
when indicated. Second, limitations of this work are related to the
study design, cross-sectional, which does not include a period of follow-
up and to the selection of patients. In relation to the ascertainment of
patients, however, we have no reason to believe that there should be
differences in the side effects of antiretroviral therapy between the
patients in our study and those attending other health units in the same
area. Moreover there are only three important reference units for HIV/
AIDS patients in the state of Pernambuco, and approximately 50% of
the patients attend the out-patients clinics of Correia Picanço hospital.
The percentage of individuals who had an increase in their glucose
levels was small (n = 10), which make comparisons difficult. It was
observed a greater frequency (7/103) of individuals with elevated
glucose levels among patients undergoing ARV treatment without PIs,
whereas found just 1.5% (2/134) of patients with elevated glucose levels
Table 4
Odds Ratio for the association between triglycerides and type of ARV
treatment, adjusted for age group, creatinine and gender in HIV positive
individuals
CI 95%
Variables Odds-ratio Inferior Superior p value
Type of ARV treatment
Never had ARV 1.0000
Treatment without PIs 1.6645 0.9406 2.9457 0.0802
Treatment with PIs 3.5287 2.0274 6.1417 < 0.0001
Age group
< 40 years 1.0000
> 40 years 2.0044 1.2193 3.2951 0.0061
Creatinine
Normal 1.0000
Elevated 1.6775 0.9833 2.8619 0.0577
Sex
Female 1.0000
Male 2.2360 1.3119 3.8110 0.0031
Table 3
Odds Ratio for the association between total cholesterol and type of ARV
treatment adjusted for age-group in HIV positive individuals
CI 95%
Variables Odds-ratio Inferior Superior p value
Age group
< 40 years 1.0000
> 40 years 1.6801 0.9735 2.8994 0.0624
Type of ARV treatment
Never had ARV 1.0000
Treatment without PIs 1.2255 0.5920 2.5370 0.5838
Treatment with PIs 2.1257 1.1033 4.0954 0.0242
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among the patients receiving PIs, but the small number limit our
conclusions. There is, however, disagreement between these findings
and those found in the literature, as a study carried out in 1999 describes
an increase in the frequency of hyperglycemia among men receiving
ARV therapy combined with PIs when compared to ARV regimens
without these drugs15. In a five-year cohort study, HIV positive patients
had plasma lipids monitored before and after the introduction of ARV
with PIs. The effects of these drugs on cholesterol and triglyceride
levels were much more frequent and important than on the glucose
levels22.
In the sample of 372 patients, 113 (30.4%) had never undergone
ARV treatment, and 246 (66.2%) were undergoing a regimen of a
combination of drugs for at least six months. This is a length of time
long enough for the development of metabolic alterations related to
the ARV treatment, as an elevation in the levels of total cholesterol
and triglycerides associated with the use of PIs may occur within the
first weeks of treatment6. In patients receiving a PI-containing ARV
regimen, the frequency of hypercholesterolemia was 27.2%, and of
hypertriglyceridemia was 41.5% (p < 0.001), these values being
significantly higher than in patients never treated with ARV regimens.
Concerning the HDL levels, we found similar results in both groups of
patients undergoing ARV treatment.
The association between increased levels of total cholesterol and
triglycerides and the PI-based antiretroviral regimens is also referred
by other authors. A prospective study with 239 patients described the
extent and time course of the PIs effects on serum lipid levels of 148
patients receiving a triple combination ARV therapy including PIs,
compared with a control group of 91 patients on therapy with two
nucleosides. In the group receiving PIs the authors found a statistically
significant increase in the total cholesterol after three, six and 12 months
(p ≤ 0.001, p ≤ 0.001 and p ≤ 0.001, respectively) in comparison to the
baseline level recorded before the beginning of the ARV treatment,
and an increase of 25.5% (p = 0.001) in the triglyceride levels from the
baseline at month 3. There was no change in the lipid levels in the
control group20. In another cohort study, investigating 113 patients
receiving ARV treatment with PIs (mean 21 months) and 45 patients
infected with HIV that had never undergone ARV treatment with PIs,
the authors observed a prevalence of hyperlipidemia of 74% at the
beginning of the study in the group treated with PIs and a prevalence
of 28% among those that had never undergone ARV treatment with
PIs. The authors also found an impaired glucose tolerance in 16% of
PIs recipients and diabetes mellitus in 7%. There was no statistically
significant difference between the two groups throughout the study5.
Other authors report an increase in the levels of total cholesterol and
triglycerides in patients receiving PIs 48 weeks after the beginning of
the ARV treatment, but with no significant change in the levels of
HDL cholesterol17. Other authors refer a high frequency of women
receiving the HAART regimen containing PIs that presented
modifications in body shape and elevated levels of serum lipids
associated to an increase in the risk of cardiovascular disease, when
compared to a similar group of women receiving the HAART regimen,
but without complaints of change in body shape7.
Besides the use of PIs, age group was shown to be independently
associated with increased levels of cholesterol in our study; when
adjusted for each other type of ARV treatment and age group remained
in the logistic model. Regarding other potential confounders, gender,
practice of exercise, glucose, creatinine and TSH levels, and the
presence of proteinuria were not associated with hypercholesterolemia.
Concerning triglycerides levels, the type of ARV treatment, gender,
age group and creatinine level emerged as significantly and
independently associated with increased triglycerides in the logistic
regression model. On the other hand no association was found between
hypertriglyceridemia and the practice of exercise, glucose level,
proteinuria and the increase of TSH and the presence of proteinuria.
Prospective studies have only evaluated the influence of clinical
signs that are suggestive of nephropathy or hypothyroidism in patients
receiving ARV therapy with PIs. They did not find an association
between the plasma lipid levels and the TSH levels, nor with the clinical
condition of nephropathy, concluding that it is unlikely the nephrotic
syndrome or hypothyroidism might have induced the observed lipid
abnormalities, which corroborates with the findings in this study16.
Information regarding diet could not be analyzed in this study,
despite having recorded the 24-hour dietary intake at the time of
collecting the blood sample. It was not possible, therefore, to determine
the potential contribution of dietary habits on the increase of the plasma
lipid levels observed in some of the individuals during the study period.
Considering the profile of associated metabolic abnormalities and
the number of years during which HIV positive patients will be exposed
to ARV therapy, it is possible to anticipate the significant impact
hyperlipidemia will have on the health of these individuals13.
The findings in this study indicate the need for a continuous
monitoring of HIV seropositive patients in ARV therapy, especially
those using PIs, for corrections whenever possible of metabolic
alterations in an attempt to alleviate the adverse effects of these drugs
on the health of these individuals. The findings recommend carrying
out well-controlled cohort studies for the evaluation of the long-term
consequences of HAART-associated hyperlipidemia; special focus on
the risk of cardiovascular diseases should be given.
RESUMO
Tratamento antiretroviral para a infecção pelo HIV/AIDS e o
risco de desenvolver hiperglicemia e dislipidemia
Um estudo epidemiológico transversal, com caráter analítico, foi
realizado para descrever características sócio-demográficas bem como
verificar a associação entre o tipo de tratamento antiretroviral
empregado e hiperglicemia e hiperlipidemia, com especial atenção
aos pacientes em uso de inibidores da protease do HIV. As informações
foram obtidas a partir de um questionário e da coleta de sangue e urina
para a execução dos exames laboratoriais. Foram entrevistados 418
pacientes, sendo que 46 indivíduos foram excluídos do estudo. A
amostra foi então composta por 372 pacientes soropositivos para o
HIV atendidos no ambulatório do Hospital Correia Picanço da
Secretaria Estadual de Saúde, no período de agosto a novembro de
2000. O teste do Qui-quadrado foi usado para testar as associações e a
regressão logística múltipla para ajustar pelos potenciais fatores de
confusão. Observou-se uma maior frequência de pacientes com níveis
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elevados de glicose entre aqueles que faziam uso de terapia
antiretroviral sem inibidores da protease, mas o pequeno número de
indivíduos limitou as comparações. Verificou-se uma associação entre
o colesterol total e o uso de inibidores da protease (p = 0,047) mesmo
após o ajuste por idade. Verificou-se também uma associação entre os
níveis de triglicerídeos e o uso de inibidores da protease que permaneceu
estatisticamente significante mesmo após o ajuste por idade, sexo e
níveis de creatinina (p < 0,001). Os níveis de glicose, de TSH, a presença
de proteinúria e a pratica de exercícios físicos não estiveram associados
com os níveis de colesterol ou com os níveis de triglicerídeos, não se
caracterizando como fatores de confusão das associações descritas.
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